DCB in PCI: Adjunctive Therapy or Standard of Care?

Published: 14 February 2022

  • Views:

    Views Icon 46314

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Learn more about the origins and science behind the DCB technology, the important clinical data supporting DCB use in the coronary arteries, existing and emerging treatment indications through videos, interviews and panel discussions with renowned faculty from highly ranked institutions.

This programme is supported by: Medtronic

Key Learning Objectives

  • To discuss the origins and science behind the DCB technology, its current and potential areas of application in various clinical scenarios, and emphasize the benefits of DCB technology vs DES and Paclitaxel vs Limus.
  • To emphasize the importance of vessel preparation, algorithms of optimal therapy delivery and criteria used for immediate results evaluation.
  • To highlight the DCB Clinical Program, understanding the clinical benefits and safety of paclitaxel DCBs, and its relevance to your daily practice

Target Audience

  • Interventional Cardiologists
  • General Cardiologists
  • Allied Healthcare Professionals

More from this programme

Part 1

Science of DCB

In episode, both physicians will discuss the origins behind the drug-coated balloons (DCBs) technology. One of the fathers of DCB technology Prof Bruno Scheller, will share a fascinating story about how a bit of luck and solid experimentation had a tremendous impact on what is now seen as a very exciting new era in cardiology. Followed by episode 2, Prof Scheller and Dr Tunev delve into an important discussion around the benefits of DCBs vs DES and PTX vs Limus, providing insights on DCB mechanisms of action and predictors of long-tern efficacy. Questions 1: How do DCBs work in the vessel? Question 2: What are the benefits of DCB vs DES? Question 3: What is the difference between the two drugs in the context of DCB?
2 sessions
Episode 1: The origins and science behind the DCB technology Watch now
Episode 2: The benefits vs DES and PTX vs Limus Watch now

Part 2

DCB: Role of Predilatation and dissection assessment

This episode sheds light on very important steps of the DCB-alone PCI - lesion preparation and dissection assessment. Prof Scheller and Dr Mylotte discuss how their practice has evolved in terms of preparing the lesion for treatment with a DCB, and share their recommendations how to manage different types of dissections. In episode 4, we learn the differences between acute results for scaffold vs no scaffold, what are the acceptable acute results and why no perfect results of DCB could be accepted and much more. Lastly, in episode 5, we learn how to integrate OCT, IVUS and FFR into decision taking as well as the importance of aggressive vessel preparation and what lesions to exclude from DCB.
3 sessions
Episode 3: DCB: Role of Predilatation and dissection assessment Watch now
Episode 4: DCB: Acute and long-term results after DCB-alone PCI Watch now
Episode 5: Risk of abrupt closure and use of adjunctive technologies Watch now

Part 3

DCB in ISR and Guidelines

As we begin Part 3 in this series, episode 6 joins Dr Azeem Latib from New York, US and Prof Azfar Zaman, London, UK discussing how DCBs are now embedded into the guidelines for ISR and how they have impacted their practice. They also review the role of DCBs in in-stent restenosis. In episode 7, we re-join Dr Azeem Latib and Prof Azfar Zaman to review the requirement for success for DCBs and vessel preparation.
2 sessions
Episode 6: DCB in ISR and Guidelines Watch now
Episode 7: Requirements for success with DCB and vessel preparation Watch now

Part 4

Drug Coated Balloons in De Novo Lesions

For Part 4, episode 8 , we join Dr Latib and Dr Eccleshall to discuss the current evidence in the industry for Drug Coated Balloons in De Novo lesions, as well as DCB in small vessel disease and DCB in large vessels. In episode 9, discover the use of DCB in De Novo lesions with Dr Azeem Latib and Dr Simon Eccleshall, whilst also taking the decision on whether a lesion is a good one for DCB only. We also discuss the approach for sizing of the lesion for DCB and consider a check list for lesion preparation and procedure success assessment. In episode 10, we rejoin Dr Azeem Latib and Dr Simon Eccleshall for the final part within Drug Coated Balloons in De Novo Lesions, to discuss what lesions need a stent and what can be safely left without. In addition Dr Latib and Dr Eccleshall consider long term outcomes of DCB treatment of De Novo Lesions and the risk of acute vessel closure with only DCB used in PCI. 

3 sessions
Episode 8: An Introduction and Current Evidence Watch now
Episode 9: Tips and Tricks Watch now
Episode 10: DCB in De Novo Lesions: Safety and Risks Watch now

Part 5

DCB in HBR. DAPT considerations

In part 5 of this series, we discuss the approach for dual antiplatelet therapy after DCB in ISR as well as the approach for dual antiplatelet therapy after DCB in de novo lesions with Dr Azeem Latib and Prof Flavio Ribicini. But what other factors need to be taken into account when thinking of DAPT duration after DCB? Don’t miss this episode to find out. In our 12th and final episode of this section, we rejoin Prof Bruno Scheller and Prof Antonio Colombo to define vessel restoration and full vasomotion, whilst also discussing the role of different devices for vasomotion. Prof Scheller and Prof Colombo also examine the role of imaging and long term benefits between DCB and DES.

2 sessions
Episode 11: DCB as a Solution for HBR Watch now
Episode 12: Full Vasomotion and Vessel Restoration: When To Go For It Watch now

Part 6

Review of Paclitaxel-Coated Balloons

For Part 6, episode 13, we will explore the complementary use of drug-coated balloons (DCB) and drug-eluting stents (DES) in various cases. We will analyse the short and long-term angiographic results associated with these treatments and focus on the positive remodelling effect observed with paclitaxel DCB. Watch now to gain valuable insights into optimising treatment outcomes and enhancing patient care with DCB and DES. In episode 14, the final episode of the series, we focus on paclitaxel-coated balloons (DCB), where we will review their safety, efficacy and positive remodelling effect. Through an analysis of bench tests, preclinical studies, and clinical evidence, participants will gain valuable insights into the benefits of using paclitaxel-coated balloons in percutaneous coronary interventions. Enhance your knowledge and make informed decisions by watching this concise and informative session.

2 sessions
Episode 13: Complex Coronary Artery Disease: Can Stents and DCB be Complementary? Watch now
Episode 14: Evidence on Efficacy & Safety of Paclitaxel Coated Balloons Watch now

Faculty Biographies

Antonio Colombo

Antonio Colombo

Director, Cardiac Cath Lab and Interventional Cardiology Unit

Personal History

Dr Colombo was born in Busto Arsizio, Italy on June 17, 1950.7 After completing his schooling in Gallarate, he went on to the University of Milan School of Medicine in 1968, before attending the University of Parma Postgraduate School to study Cardiovascular Medicine. From a young age, he was a gifted student; and ultimately graduated Summa Cum Laude from his medical school.7

In 1967, Dr Colombo’s love of travel took him all the way to Iran in his Volkswagen (which he affectionately named “Maggiolino”).5 In 1986, he opened a private centre based on his innovative ideas after feeling ostracised by the academic environment.5 At the American College of Cardiology Scientific Session in 2012, Dr Colombo was dubbed a “Legend in Cardiovascular Disease.”2

He and his wife have two children.7

Dr Colombo is famous for his relentless work ethic, usually…

View full profile
Bruno Scheller

Bruno Scheller

Dr Bruno Scheller studied medicine at the University of Saarland, Germany, from 1988 til 1994. Since 1994 he has been working as a physician at the clinic for internal medicine III,, University Hospital of Saarland, Homburg/Saar, Germany, where he is a consultant for internal medicine, cardiology, and intensive care. He is a full professor for Clinical and Experimental Interventional Cardiology at the Medical School of the University. 

View full profile